Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
Trial details
- Registry ID
- NCT04957485
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as JYNNEOS
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOSNCT04957485 | SIGA Technologies | Phase 2 | Active not recruiting | 2027-01-01Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |